Moreover, the CVD-REAL had a positive outcome of lowering the risk of heart failure progression and death in patients with T2DM who were prescribed SGLT-2 inhibitors, which were statistically significant [31]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.